多中心CYP2C19基因型指导抗血小板治疗实施策略调查
本文比较了12个早期实施CYP2C19基因型指导经皮冠状动脉介入术后抗血小板治疗的机构的实施策略,描述了常见问题的解决方案和初步性能指标。项目间关键差异包括检测结果周转时间和治疗改变时机,均与CYP2C19检测模型和平台相关。实施需要新的信息学基础设施、药师等专家解读结果、医师倡导者及持续教育。
要点
- 检测结果周转时间和治疗改变时机因检测模型和平台而异。
- 实施需要信息学基础设施、药师解读、医师倡导和持续教育。
- 共识经验可为机构内实施类似临床药物基因组学项目提供路径。
核心结论
- CYP2C19基因型指导抗血小板治疗的实施策略在检测平台、结果沟通、临床决策支持、教育培训和证据转化等方面存在挑战,12个早期实施者的经验可提供参考。
研究设计与样本
- 比较12个早期实施CYP2C19基因型指导抗血小板治疗项目的实施策略,描述常见问题解决方案和初步性能指标。
主要发现
- 项目间关键差异包括检测结果周转时间和治疗改变时机,均与CYP2C19检测模型和平台相关。
- 实施机构报告需要新的信息学基础设施、药师等专家解读结果、医师倡导者和持续教育。
临床怎么用
- 实施CYP2C19基因型指导抗血小板治疗时需考虑检测平台选择、结果沟通、临床决策支持、教育培训和信息学基础设施。
- 需要药师等专家解读结果并建立医师倡导和持续教育机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CYP2C19 genotype-guided antiplatelet therapy following percutaneous coronary intervention is increasingly implemented in clinical practice. However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption. In this report, we compare and contrast implementation strategies of 12 early adopters, describing solutions to common problems and initial performance metrics for each program. Key differences between programs included the test result turnaround time and timing of therapy changes, which are both related to the CYP2C19 testing model and platform used. Sites reported the need for new informatics infrastructure, expert clinicians such as pharmacists to interpret results, physician champions, and ongoing education. Consensus lessons learned are presented to provide a path forward for those seeking to implement similar clinical pharmacogenomics programs within their institutions.
引用
- Empey PE, Stevenson JM, Tuteja S, et al. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. Clin Pharmacol Ther. 2018. PMID: 29280137. doi:10.1002/cpt.1006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。